GalNAc is a carbohydrate moiety that binds to ASGPR with high affinity and facilitates the uptake of siRNAs into liver hepatocytes via clathrin‐mediated endocytosis.[31] GalNAc‐conjugated siRNAs can specifically target hepatocyte‐deregulated genes for the treatment of liver diseases, making them attractive therapeutic tools. The gene discussed is ASGR1; the disease is liver disorder.